Tremfya

Johnson and Johnson Submits FDA Request for Pediatric Tremfya Approval
Managed Healthcare Executive
Mon, 12/2/24 - 07:17 pm
JNJ
Tremfya
pediatric
psoriasis
juvenile psoriatic arthritis
Dueling IL-23 data drop as Lilly, J&J await FDA decisions in Crohn's
First Word Pharma
Mon, 10/28/24 - 06:24 pm
Eli Lilly
JNJ
Crohn's Disease
FDA
clinical trials
Tremfya
Omvoh
J&J, Eli Lilly pad immunology profiles with trial readouts in new patient groups
Fierce Pharma
Fri, 10/25/24 - 11:43 am
JNJ
Eli Lilly
Tremfya
immunology
plaque psoriasis
Ebglyss
atopic dermatits
Tremfya, Carvykti sales grow as J&J prepares for Stelara patent loss
BioPharma Dive
Wed, 10/16/24 - 05:19 pm
JNJ
Carvykti
Tremfya
Stelara
patents
FDA expands J&J's psoriasis drug for inflammatory bowel disease
Reuters
Wed, 09/11/24 - 10:59 pm
JNJ
Tremfya
FDA
ulcerative colitis
J&J’s Blockbuster Tremfya Flops in Phase II Giant Cell Arteritis Trial
BioSpace
Tue, 06/25/24 - 11:33 am
JNJ
Tremfya
clinical trials
giant cell arteritis
J&J Positions Tremfya as Stelara Successor with Strong Head-to-Head Data
BioSpace
Wed, 05/22/24 - 11:33 am
JNJ
Tremfya
Stelara
Crohn's Disease
J&J’s Tremfya meets endpoints in Phase III ulcerative colitis trial
Clinical Trials Arena
Tue, 05/21/24 - 11:17 am
JNJ
Tremfya
ulcerative colitis
clinical trials
Johnson & Johnson files sBLA for ulcerative colitis treatment
Pharmaceutical Business Review
Tue, 03/12/24 - 11:19 am
JNJ
FDA
Tremfya
ulcerative colitis
Janssen tackles racial gap in Phase IIIb psoriasis trial with Tremfya
Clinical Trials Arena
Fri, 10/20/23 - 11:39 am
Janssen
psoriasis
Tremfya
clinical trials
Janssen’s Tremfya maintains three years of remission in Phase II Crohn’s disease trial
Clinical Trials Arena
Tue, 10/17/23 - 11:45 am
JNJ
Janssen
clinical trials
Crohn's Disease
Tremfya
Johnson & Johnson’s Tremfya outshines IL-17 inhibitors as plaque psoriasis treatment
Clinical Trials Arena
Thu, 05/25/23 - 12:48 pm
JNJ
Janssen
Tremfya
psoriasis
real world data
Top 10 Pharma TV Ad Spenders in 2022 — Anti-Inflammatories and Diabetes Drugs Dominate
Xtalks
Sun, 01/29/23 - 01:31 pm
television ads
pharma marketing
DTC ads
AbbVie
Rinvoq
Dupixent
Sanofi
Regeneron
Skyrizi
Novo Nordisk
Ozempic
Jardiance
Eli Lilly
Boehringer Ingelheim
Rybelsus
Trulicity
Rexulti
Otsuka
Lundbeck
Tremfya
JNJ
Verzenio
New TREMFYA Data Show an Overall Clinical Response Rate of Approximately 80 Percent in a Phase 2b Induction Study of Adults with Moderately to Severely Active Ulcerative Colitis
Marketscreener
Tue, 10/25/22 - 10:53 am
JNJ
Janssen
clinical trials
ulcerative colitis
Tremfya
Janssen Presents New Data that could Set Anti-Inflammatory Drug Apart
BioSpace
Thu, 05/19/22 - 09:00 pm
JNJ
Janssen
Tremfya
Skyrizi
AbbVie
anti-inflammatories
J&J lands Tremfya one-two punch in IBD with first ulcerative colitis win and long-term Crohn's data
Fierce Pharma
Mon, 02/21/22 - 10:37 am
JNJ
Janssen
Tremfya
Crohn's Disease
J&J touts Tremfya win in Humira-resistant psoriatic arthritis patients amid showdown with AbbVie's Skyrizi
Fierce Pharma
Thu, 06/3/21 - 10:51 pm
JNJ
Tremfya
psoriatic arthritis
AbbVie
Skyrizi
Janssen's Psoriatic Arthritis Drug Proves Long-Term Efficacy in Two-Year Trial
BioSpace
Tue, 03/16/21 - 10:40 pm
JNJ
Janssen
clinical trials
Tremfya
psoriatic arthritis
Janssen’s Tremfya gets FDA approval for active psoriatic arthritis
Pharmaceutical Business Review
Wed, 07/15/20 - 10:20 am
Janssen
JNJ
FDA
Tremfya
psoriatic arthritis
Johnson & Johnson's Tremfya backs psoriatic arthritis play with newest data
Fierce Pharma
Tue, 11/12/19 - 10:03 am
JNJ
Tremfya
psoriatic arthritis
psoriasis
clinical trials

Pages